Company / Accounts Receivable
Xenon Pharmaceuticals Inc. Accounts Receivable History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.5M
FY2024
5-year range
$874.0K / $2.8M
FY2020-FY2024
Trend
+68.1%
vs FY2023
Sector context
#103 of 113
Health Care
What the data says
Among 113 Health Care companies, Xenon Pharmaceuticals Inc. is in the bottom 9% for accounts receivable. Accounts Receivable returned to growth in FY2024 after 2 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2024 with a 5-year CAGR of +12.6%.
Improved from $986,000 to $1M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -19.0%
- 5-Year CAGR
- +12.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 113This company $1.5M Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.6%, indicating consistent growth.
- In FY2024, accounts receivable increased 68.1% year-over-year.
- Ranks #103 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.5M | +68.1% |
| FY2023 | $874.0K | -11.4% |
| FY2022 | $986.0K | -64.3% |
| FY2021 | $2.8M | +51.8% |
| FY2020 | $1.8M | +124.1% |
| FY2019 | $813.0K | +438.4% |
| FY2018 | $151.0K | -65.5% |
| FY2017 | $438.0K | +119.0% |
| FY2016 | $200.0K | -36.5% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026